Is Rafael Holdings, Inc. a good investment? Rafael Holdings, Inc. (RFL) is currently trading at 1.07 USD.
Earnings Schedule: Rafael Holdings, Inc. is expected to release its next earnings report on Dec. 10, 2026.
No, it does not currently pay a dividend.
Rafael Holdings, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Dec. 10, 2026. The company currently has a trailing EPS of -0.58.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C (NPC), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate. The company is also involved in developing Promitil, a pegylated liposomal mitomycin-C lipidic prodrug which is designed molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form. In addition, it develops surgical and procedural devices, including orthopedic arthroscopy instrument for carpal and cubital tunnel syndrome. Further, the company provides technological solutions specifically engineered for increased bioavailability of cannabinoids. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
| Year | Total Dividends |
|---|---|
| ▸2009 |
0.04 USD
|
| Dec. 31, 2009 | 0.0200 |
| June 30, 2009 | 0.0200 |
| Split Date | Split Ratio to 1 |
|---|---|
| May 9, 2025 | 1.01 |
Community Discussion